Alteplase: Difference between revisions

 
No edit summary
Line 1: Line 1:
#REDIRECT[[Thrombolysis in Acute Ischemic Stroke (tPA)]]
==Administration==
*Type: [[Thrombolytic]]
*Dosage Forms:
*Routes of Administration: IV
*Common Trade Names: tPA
 
==Adult Dosing==
*Acute [[MI]]:
**>67kg: 15mg IV over 1-2min; then 50mg IV over 30min; then 35mg over next 60min (i.e. 100mg over 1.5hr)
**≤67kg: 15mg IV over 1-2min; then 0.75 mg/kg (max 50mg) IV over 30 min; then 0.5 mg/kg over 60min (max 35 mg)
*Acute [[ischemic stroke]]:
**0.9mg/kg IV (max 90mg total)
***10% of dose is administered as bolus; rest is given over 60min
*Massive [[PE]]::
**100mg IV over 2hr OR 0.6mg/kg over 2min
**See also: [[EBQ:Thrombolysis in Pulmonary Embolism Metanalysis]]
*Arterial thrombosis:
**1.5 mg/hour by transcatheter intra-arterial infusion until lysis of thrombus
 
==Pediatric Dosing==
*[[PE]]: 0.5 mg/kg/hour IV, for a maximum of 6 hours, in addition to heparin
 
==Special Populations==
*[[Drug Ratings in Pregnancy|Pregnancy Rating]]: C
*[[Lactation risk categories|Lactation risk]]: Infant risk cannot be ruled out
*Renal dosing: not defined
*Hepatic dosing: not defined
 
==Contraindications==
*Allergy to class/drug
*Bleeding diathesis
*Active internal bleeding
*Current intracranial hemorrhage, subarachnoid hemorrhage
*Intracranial neoplasm, arteriovenous malformation, aneurysm, or other conditions that may increase the risk of intracranial bleeding
*Recent (<3 mo) intracranial or intraspinal surgery
*Recent (<3 mo) serious head trauma
*Recent (<3 mo) stroke (for patients being treated for MI or PE)
*Severe uncontrolled hypertension
 
==Adverse Reactions==
===Serious===
*Bleeding!
*GI bleed
*Pericardial effusion, pericarditis, cardiac tamponade
*Intracranial hemorrhage, cerebral herniation
*Stroke, seizure
*Anaphylaxis, angioedema
*Pulmonary edema, pleural effusion
*Cardiac dysrhythmia
===Common===
 
==Pharmacology==
*Onset of action: 30-60 minutes
*Half-life: 26.5 to 46 minutes
*Metabolism: Liver
*Excretion:
 
==Mechanism of Action==
*Tissue plasminogen activator (TPA): binds fibrin, enhances conversion of plasminogen to plasmin thus initiating fibrinolysis
 
==Comments==
 
==See Also==
*[[Thrombolytics]]
*[[Thrombolysis in Acute Ischemic Stroke (tPA)]]
*[[EBQ:Thrombolysis in Pulmonary Embolism Metanalysis]]
*[[Acute arterial ischemia]]
*[[STEMI]]
 
==References==
<references/>
[[Category:Pharmacology]]

Revision as of 21:09, 22 December 2016

Administration

  • Type: Thrombolytic
  • Dosage Forms:
  • Routes of Administration: IV
  • Common Trade Names: tPA

Adult Dosing

  • Acute MI:
    • >67kg: 15mg IV over 1-2min; then 50mg IV over 30min; then 35mg over next 60min (i.e. 100mg over 1.5hr)
    • ≤67kg: 15mg IV over 1-2min; then 0.75 mg/kg (max 50mg) IV over 30 min; then 0.5 mg/kg over 60min (max 35 mg)
  • Acute ischemic stroke:
    • 0.9mg/kg IV (max 90mg total)
      • 10% of dose is administered as bolus; rest is given over 60min
  • Massive PE::
  • Arterial thrombosis:
    • 1.5 mg/hour by transcatheter intra-arterial infusion until lysis of thrombus

Pediatric Dosing

  • PE: 0.5 mg/kg/hour IV, for a maximum of 6 hours, in addition to heparin

Special Populations

Contraindications

  • Allergy to class/drug
  • Bleeding diathesis
  • Active internal bleeding
  • Current intracranial hemorrhage, subarachnoid hemorrhage
  • Intracranial neoplasm, arteriovenous malformation, aneurysm, or other conditions that may increase the risk of intracranial bleeding
  • Recent (<3 mo) intracranial or intraspinal surgery
  • Recent (<3 mo) serious head trauma
  • Recent (<3 mo) stroke (for patients being treated for MI or PE)
  • Severe uncontrolled hypertension

Adverse Reactions

Serious

  • Bleeding!
  • GI bleed
  • Pericardial effusion, pericarditis, cardiac tamponade
  • Intracranial hemorrhage, cerebral herniation
  • Stroke, seizure
  • Anaphylaxis, angioedema
  • Pulmonary edema, pleural effusion
  • Cardiac dysrhythmia

Common

Pharmacology

  • Onset of action: 30-60 minutes
  • Half-life: 26.5 to 46 minutes
  • Metabolism: Liver
  • Excretion:

Mechanism of Action

  • Tissue plasminogen activator (TPA): binds fibrin, enhances conversion of plasminogen to plasmin thus initiating fibrinolysis

Comments

See Also

References